PITTSBURGH — Why is Carmell Therapeutics, poised to become the newest public company in the Pittsburgh region, taking that big step? CEO Randy Hubbell said it’s the right move for the Pittsburgh-based biotech company, which is a spinout of Carnegie Mellon University and is getting ready for the day when its first products will be commercialized.
Carmell, which began in 2008, fits in a space that isn’t easily categorized in the life sciences industry. It has developed plasma-based bioactive materials, which go into the body and safely deliver biologic medicine to either help bones or tissues heal quickly.
Read more from the Pittsburgh Business Times.
This browser does not support the video element.